


BD Veritor™ Plus System

Rapid point-of-care COVID-19 testing*


1

Sample collection



2

Sample preparation



Dos and don'ts of sample collection

- Do test sample immediately.
- Use only swabs and reagents provided with the kit.
- Refer to: Interim Guidelines for Collecting, Handling and Testing Clinical Specimens from persons for COVID-19 at <https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html>




Continued on back

3

Sample testing


Analyze Now mode



Add 3 drops to the test device sample well



Wait 15 minutes and then press the power button



Once prompted on-screen, insert the test device into the Analyzer

Results are displayed within seconds


Walk Away mode



Press the power button.






When prompted, double-click for Walk Away mode



Add 3 drops to the test device sample well

Insert the test device into the Analyzer

Results are displayed after 15 minutes



For combined COVID-19 & Flu A+B testing, results for Flu A and Flu B will also be displayed on-screen with SARS-CoV-2 results.

BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B Instructions for Use, package insert. Franklin Lakes, NJ: Becton, Dickinson and Company.

Emergency Use Authorization Information for the BD Veritor™ SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays:

- These products have not been FDA cleared or approved; but have been authorized by FDA under EUA for use by authorized laboratories
- The BD Veritor™ System for Rapid Detection of SARS-CoV-2 has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and,
- These products are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

